Atlantic Edge Private Wealth Management’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-500
Closed -$4.41K – 585
2025
Q3
$4.41K Hold
500
– – ﹤0.01% 449
2025
Q2
$3.19K Hold
500
– – ﹤0.01% 451
2025
Q1
$2.43K Hold
500
– – ﹤0.01% 450
2024
Q4
$4.78K Hold
500
– – ﹤0.01% 394
2024
Q3
$4.17K Hold
500
– – ﹤0.01% 415
2024
Q2
$3.41K Hold
500
– – ﹤0.01% 402
2024
Q1
$1.26K Hold
500
– – ﹤0.01% 451
2023
Q4
$1.2K Buy
+500
New +$1.18K ﹤0.01% 434

Other funds holding EBS

Atlantic Edge Private Wealth Management's EBS Position: Q4 2025 in Review

Atlantic Edge Private Wealth Management sold out of Emergent Biosolutions (EBS) in Q4 2025, closing a stake of 500 shares — an estimated $4.41K sold.

Atlantic Edge Private Wealth Management first reported a position in EBS in Q4 2023 and held it in 8 quarters. The position peaked at $4.78K in Q4 2024. 183 funds tracked by Wall St. Rank hold EBS as of Q4 2025.

  • Atlantic Edge Private Wealth Management reported no remaining Emergent Biosolutions position as of Q4 2025 after selling out during the quarter.
  • Atlantic Edge Private Wealth Management sold 500 Emergent Biosolutions shares in Q4 2025, an estimated $4.41K.
  • Atlantic Edge Private Wealth Management first reported a position in Emergent Biosolutions in Q4 2023 and held it in 8 quarters.
  • Atlantic Edge Private Wealth Management's Emergent Biosolutions position peaked at $4.78K in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2025.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q4 2025, filed 27 Jan 2026.